Myelogenous Leukemia

Myelogenous leukemia is a cancer of blood-forming tissue, especially the bone marrow, where many blood cells are made. In chronic myelogenous leukemia, also called chronic myeloid leukemia or CML leukemia, abnormal myeloid cells build up in the blood and bone marrow. Symptoms and the course of myelogenous leukemia can vary from person to person. Some people have few or no symptoms at first, while others develop noticeable changes in their blood counts or overall health.

Most cases of chronic myelogenous leukemia are linked to an acquired change involving chromosomes 9 and 22. This change creates the BCR::ABL1 fusion gene, which sends signals that cause abnormal myeloid cells to grow and survive. It usually develops during a person’s lifetime rather than being inherited from a parent. Having this change is not generally considered something a person caused through lifestyle or everyday choices.

Many people with chronic myelogenous leukemia have no identifiable or modifiable risk factor. Ordinary lifestyle choices, such as diet or exercise habits, are not established causes of this disease.

When chronic myeloid leukemia is uncontrolled or progresses, it may contribute to anemia, a higher risk of infection, bleeding, an enlarged spleen, or progression to an accelerated or blast phase. Chronic myeloid leukemia treatment can also cause effects that vary by medication, such as fatigue, nausea or other gastrointestinal symptoms, fluid retention, muscle cramps, skin changes, or changes in blood counts. Report concerning effects to the oncology team, which can adjust supportive care or treatment when appropriate; do not stop a prescribed medicine without medical guidance.

Evaluation commonly begins with a complete blood count and a blood smear to examine the number and appearance of blood cells. When indicated, a bone marrow evaluation provides additional information about blood-forming cells. Molecular or chromosome testing can identify the BCR::ABL1 change associated with CML and help confirm the diagnosis. Clinicians also consider symptoms, blood counts, molecular response, and treatment response when assessing the disease over time.

Unlike many solid tumors, chronic myeloid leukemia is usually described by chronic, accelerated, and blast phases rather than by stage numbers such as stage I or stage IV. Molecular response, blood counts, symptoms, and how well treatment is working help guide monitoring and next steps. An ICD-10 code for chronic myeloid leukemia is a billing and record-keeping code; it is not the same as a disease phase or a measure of prognosis.

An allogeneic stem cell transplant uses blood-forming stem cells from a donor and may offer an important option for some people with advanced disease or a poor response to targeted medicines. It also carries significant risks, so a transplant specialist must evaluate the potential benefits and harms for the individual.

Long-term monitoring usually includes blood counts, molecular testing, discussions about taking medicines as prescribed, and review of medication interactions and side effects. Decisions about reducing or stopping treatment are individualized and should be made with the treating hematology team after an appropriate response and monitoring plan are established. The best drugs for chronic myeloid leukemia differ according to the person’s disease and health needs.

The outlook for chronic myelogenous leukemia depends on the disease phase at diagnosis, age and overall health, blood and molecular findings, response to treatment, and ability to tolerate the chosen medicine. It is also influenced by whether treatment resistance or disease progression develops. Regular testing helps the care team understand response and identify changes that may require a different approach.

Follow-up for CML commonly includes scheduled blood counts, molecular testing, medication review, and assessment of side effects. The care team also looks for signs of a loss of treatment response, resistance, or progression. The timing of visits and tests depends on the treatment plan, response, and overall health.